A new trial from Karolinska Institutet, published in JAMA Network Open in May 2026, shifts that focus deliberately. Researchers Hampus Yngwe and Johan Lundberg enrolled 35 participants with recurring depression — people who had experienced multiple depressive episodes but were not classified as treatment-resistant. That distinction is not a minor methodological footnote. It is the study’s central contribution, and it matters because if psilocybin can help this broader population, the implications for mental health care would be considerably wider than the treatment-resistant studies that preceded it.
What the study did
Participants were randomly assigned to receive either a single oral dose of 25 mg of psilocybin or a placebo — vitamin B3, chosen because it produces some mild physical sensations, such as temporary skin flushing, that could plausibly mimic the early bodily signals of a psychedelic experience. The 25 mg dose is consistent with the dosing used in most comparable psilocybin depression trials. Both groups received the same psychological support before, during, and after dosing: structured preparation sessions and integration conversations with trained therapists. The aim was to hold the relational and therapeutic context constant, so that any difference in outcomes could be attributed more cleanly to the drug itself.
The follow-up ran for a full year, which is longer than many comparable trials and gave the researchers a chance to observe how the effects evolved — and whether they held.
It is worth noting that psilocybin remains a controlled substance in most countries and is not currently an approved treatment for depression anywhere. This trial was conducted under research authorisation; the therapeutic framework it describes does not yet exist as a regulated clinical option outside of specific trial settings.
What it found
The early signal was striking. By day eight — just over a week after dosing — participants in the psilocybin group were already reporting noticeable improvements in mood. Standard antidepressants typically take four to six weeks to produce meaningful effects, assuming they work at all. That speed — days rather than weeks — is one of the things that keeps drawing researchers to psilocybin: the mechanism, whatever it is, appears to act on a different timescale than conventional pharmacology.
By the end of the six-week follow-up period, more than half of the participants who received psilocybin no longer met the clinical criteria for depression. In the placebo group, only one person showed the same level of improvement. The gap between groups narrowed after that point — which the researchers note is not unusual, since recurrent depression often fluctuates naturally over time — but on self-rated outcomes the psilocybin group maintained a measurable advantage for just over three months.
One detail worth sitting with: roughly one third of participants in both groups started antidepressant medication during the follow-up period, on average around four months after the trial began. This was not a controlled part of the design, but it does reflect what real-world patients do — they seek additional help when they feel they need it, and the trial’s structure allowed for that. It also complicates any simple reading of the long-term data.
Why speed matters here
For people with recurrent depression, a faster-acting treatment is not merely a quality-of-life improvement. Depressive episodes have real costs — to work, to relationships, to the accumulation of small daily decisions that shape a life. If a single guided psilocybin session could meaningfully compress the length of a depressive episode, the benefit would extend far beyond the individual. It would also raise a different set of questions about how treatment is structured: not as a daily medication taken indefinitely, but as an occasional intervention timed to the rhythm of someone’s illness.
That framing applies much more broadly to the population studied here than to treatment-resistant cases. People with recurrent but not refractory depression — who have likely already used standard antidepressants with partial or inconsistent success — are far more numerous. Reaching them is a different challenge than reaching those for whom every previous option has failed.
Honest limits
The trial was small: 35 participants is enough to observe a signal, not enough to establish one with confidence. Larger, better-powered replication is the obvious next step, and the authors know it.
There is also the blinding problem, which bears mentioning because intellectual honesty requires it. Almost all participants correctly guessed whether they had received psilocybin or placebo — largely because the altered state produced by psilocybin is, to put it plainly, unmistakable. Expectations can shape self-reported outcomes, and the direction of that shaping is not neutral: participants who knew they had received an active treatment may have felt hope; those who felt nothing may have felt disappointed. Both responses could influence how people rate their mood in the weeks that follow. The researchers acknowledge this, and it remains one of the unresolved methodological challenges for the field as a whole.
Two participants in the psilocybin group experienced severe and persistent anxiety that required medical attention. Lead author Yngwe was direct about this: “The treatment is not risk-free and some patients may need extra support.” The trial was otherwise generally well tolerated, but that figure is worth holding alongside the positive headline numbers.
Where the field goes from here
The JAMA Network Open paper adds meaningfully to a body of evidence that was already growing, and as ScienceAlert noted in its coverage, the findings are consistent with what earlier work suggested about speed and duration. What this trial does differently is widen the aperture. The question is no longer only whether psilocybin can help the people medicine has already largely failed. It is whether psilocybin can help the people medicine helps inconsistently — which is a much larger group, and arguably a harder question to answer with rigor.
Larger trials are underway. The regulatory and clinical frameworks needed to deliver this kind of treatment at scale — trained therapists, appropriate settings, structured integration — are being built in some places, slowly. In others, the conversation has not yet started. The distance between a promising Phase 2 trial and an accessible treatment option is considerable, and the path is not straight. But the direction of the evidence is consistent, and the population it now points toward is considerably larger than the one it started with.
Source: Yngwe H & Lundberg J, Karolinska Institutet. “Psilocybin vs placebo in recurrent depression.” JAMA Network Open, May 2026. DOI: 10.1001/jamanetworkopen.2026.12589.
